Breaking News, Collaborations & Alliances

MedImmune, NGM in Diabetes Development Pact

MedImmune will have the option to license in EEC targets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MedImmune, AstraZeneca’s global biologics R&D arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialize therapeutics from NGM’s enteroendocrine cell (EEC) program for the treatment of type 2 diabetes and obesity. The two companies will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license in these EEC targets, and will be responsible for t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters